International PFO Consortium
Recruiting
Phase N/A Results N/ASummary of Purpose
The prevalence of patent foramen ovale (PFO) is about 25% in the general population and approximately 40% in patients who have ischemic stroke of unknown cause (cryptogenic stroke). Given the large number of asymptomatic patients, no primary prevention is currently recommended. On the contrary, secondary prevention is very important. Prospective studies have shown that antithrombotic treatment (ATT) with aspirin...
Read More →Trial Milestones
The following dates are available for this trial. Trial information last updated on 30 January 2012.
| 1 Jan 2009 | 6 Mar 2009 | 1 Dec 2014 | 1 Jun 2015 | 1 Jan 2012 | Unavailable |
| Start Date | First Received | 1st Completion | Completion | Verification | Results |
|---|
Trial Design
- Observation: Cohort
- Perspective: Prospective
- Sampling: Non-Probability Sample
Contacts
- Marie-Luise Mono, MD
- Krassen Nedeltchev, MD
View Trial Locations
Recruitment
- Enrollment: 1,500
- Gender: Both
- Minimum Age: 18 Years
- Accepts Healthy Volunteers: No
- 18 locations, 5 countries
Principal Investigators
- Marie-Luise Mono, MD
- Marcel Arnold, MD
- Krassen Nedeltchev, MD
University of Bern and Triemli Municipal Hospital Zurich
